A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Enzalutamide (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Rilimogene galvacirepvec; Rilimogene glafolivec
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 28 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.